Medtronic has shared that Paolo Di Vincenzo will join the company as president of its neuromodulation business, effective 30 October 2023. In this role, Di Vincenzo will be responsible for the overall strategic direction of the Medtronic neuromodulation business and its day-to-day operations.
Di Vincenzo will join Medtronic from Smith+Nephew, where he was senior vice president and general manager of Advanced Wound Management in the USA. During his nine-year tenure with the company, he also served in global marketing and leadership roles.
Prior to Smith+Nephew, Di Vincenzo held various marketing leadership roles of increasing responsibility at Systagenix (then Acelity), Becton Dickinson, and Roche Diagnostics.
“Paolo is a results-driven leader who puts people first,” said Brett Wall, executive vice president and president, Neurosciences Portfolio at Medtronic. “I am thrilled to have him join this team as neuromodulation moves into the era of personalised medicine with sensing technology. He will play a key role in advancing our capabilities in these areas while driving business execution in alignment with Medtronic’s focus on a performance-driven culture.”
The neuromodulation business is part of the Neurosciences Portfolio at Medtronic and is comprised of Pain Interventions and Brain Modulation, which engineer innovative therapies and technologies to help patients relieve pain, restore function, and reclaim movement, the company notes in a press release.
